Trenz Kristina, Lugowski Sebastian, Jahrsdörfer Ute, Jainta Silke, Vogel Walther, Speit Günter
Universitätsklinikum Ulm, Abteilung Humangenetik, Ulm D-89070, Germany.
Mutat Res. 2003 Nov;544(2-3):279-88. doi: 10.1016/j.mrrev.2003.06.011.
We are studying the induction and repair of DNA damage in lymphocytes of women from families with familial breast cancer and mutations in the breast cancer susceptibility genes BRCA1 and BRCA2. Our previous results indicated a close relationship between the presence of a BRCA1 mutation and sensitivity for the induction of micronuclei by gamma irradiation and hydrogen peroxide (H2O2). To further characterize the mutagen sensitivity and to better understand the underlying mechanisms, we now tested the effect of various cytostatics on the micronucleus frequencies in lymphocytes of women with various BRCA1 mutations in comparison to controls. The results presented here indicate enhanced sensitivity towards bleomycin, cisplatin, cyclophosphamide and bischloroethylnitosurea (BCNU). However, mutagen sensitivity towards cisplatin and BCNU was not accompanied by enhanced induction of sister chromatid exchanges (SCE), suggesting that intrachromosomal recombination is not affected. In contrast to the various DNA-damaging agents, there was no clear difference in the response to vincristine and taxol. FISH analysis revealed that the two aneugens mainly induced centromere-positive micronuclei to a similar extent in lymphocytes with and without a BRCA1 mutation. We conclude that cells containing a heterozygous mutation in BRCA1 are more sensitive towards different kinds of DNA damage in accordance with the proposed central role of BRCA1 in maintaining genomic integrity. Although BRCA1 has been shown to interact with the mitotic spindle, spindle poisons do not cause enhanced induction of micronuclei. Since some of the DNA-damaging mutagens tested here are used as cytostatics in breast cancer chemotherapy, it might be that women with a BRCA1 mutation are at higher risk for the induction of mutations and secondary cancers by standard therapies.
我们正在研究患有家族性乳腺癌且乳腺癌易感基因BRCA1和BRCA2发生突变的家族中女性淋巴细胞内DNA损伤的诱导与修复情况。我们之前的研究结果表明,BRCA1突变的存在与γ射线和过氧化氢(H2O2)诱导微核之间存在密切关系。为了进一步明确诱变敏感性并更好地理解其潜在机制,我们现在测试了各种细胞抑制剂对不同BRCA1突变女性淋巴细胞微核频率的影响,并与对照组进行比较。此处呈现的结果表明,这些女性对博来霉素、顺铂、环磷酰胺和双氯乙基亚硝脲(BCNU)更为敏感。然而,对顺铂和BCNU的诱变敏感性并未伴随姐妹染色单体交换(SCE)诱导的增强,这表明染色体内重组未受影响。与各种DNA损伤剂不同,对长春新碱和紫杉醇的反应没有明显差异。荧光原位杂交(FISH)分析显示,这两种非整倍体诱导剂在有和没有BRCA1突变的淋巴细胞中诱导着丝粒阳性微核的程度相似。我们得出结论,根据BRCA1在维持基因组完整性中所提出的核心作用,含有BRCA1杂合突变的细胞对不同类型的DNA损伤更为敏感。尽管已证明BRCA1与有丝分裂纺锤体相互作用,但纺锤体毒物不会导致微核诱导增强。由于此处测试的一些DNA损伤诱变剂在乳腺癌化疗中用作细胞抑制剂,携带BRCA1突变的女性可能因标准疗法而有更高的诱导突变和继发癌症的风险。